Reshape Lifesciences INC 8-K filings
ReShape Lifesciences has entered into an agreement for a $5 million equity line of credit to support working capital and general corporate purposes.
ReShape Lifesciences is set to merge with Vyome Therapeutics and sell assets to Biorad Medisys, pending shareholder approval and regulatory filings.
ReShape Lifesciences has received a notice from Nasdaq for failing to maintain the minimum required stockholders' equity of $2.5 million, putting its listing status at risk.
ReShape Lifesciences announced its third quarter 2024 financial results, highlighting revenue growth and a strategic merger and asset sale.
ReShape Lifesciences has entered into a securities purchase agreement for a $833,333 senior secured convertible note with an institutional investor.
ReShape Lifesciences has enacted a 1-for-58 reverse stock split, effective for trading on September 23, 2024.
ReShape Lifesciences has entered into a merger agreement with Vyome Therapeutics and an asset purchase agreement with Biorad Medisys, while also reporting a significant reduction in operating expenses.
ReShape Lifesciences will combine with Vyome Therapeutics in an all-stock merger, while simultaneously selling its assets to Biorad Medisys for $5.16 million.
ReShape Lifesciences announced its first quarter 2024 financial results, showcasing a significant reduction in operating expenses and the ongoing commercial launch of its Lap-Band 2.0 FLEX.
ReShape Lifesciences has been granted a second extension until October 7, 2024, to regain compliance with Nasdaq's minimum $1.00 bid price requirement.
ReShape Lifesciences Inc. has replaced its independent auditor, RSM US LLP, with Haskell & White LLP, effective April 8, 2024.
ReShape Lifesciences reported a decrease in 2023 revenue due to GLP-1 drug competition but is implementing a significant cost reduction plan and launching its next-generation Lap-Band 2.0 FLEX.
ReShape Lifesciences Inc. held its annual meeting on February 23, 2024, where stockholders approved the election of directors, a potential reverse stock split, and other key proposals.
ReShape Lifesciences received a delisting notice from Nasdaq for not holding an annual shareholder meeting and subsequently amended its bylaws to reduce the quorum requirement for shareholder meetings.